Iganef-9 Tab (Budesonide) 3MG

Budesonide binds to glucocorticoid receptors inside cells, forming a complex that moves into the nucleus and alters gene expression. This process suppresses the production of pro‑inflammatory cytokines and inhibits immune cell migration, resulting in decreased inflammation in the affected tissues.

The appropriate dose of Iganef-9 Tab is determined by the prescribing clinician based on the specific indication, disease severity, and patient characteristics. Dosage regimens are individualized and should follow the prescriber’s instructions without deviation.

Budesonide is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order Iganef-9 Tab, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with systemic corticosteroids, budesonide has high first‑pass metabolism, resulting in lower systemic exposure and fewer classic steroid side effects. It provides potent local anti‑inflammatory activity in the gut, making it a preferred option for targeted treatment of inflammatory bowel disease when oral delivery is appropriate.

Iganef-9 Tab should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Iganef-9 Tab is taken orally. Swallow the tablet whole with a glass of water, preferably with food to reduce gastrointestinal irritation. Follow the dosing schedule prescribed by the healthcare professional and do not crush or chew the tablet unless instructed otherwise.

The most serious risks include adrenal suppression, which can lead to fatigue and hypotension, severe hypersensitivity reactions such as rash or anaphylaxis, and long‑term bone loss resulting in osteoporosis. Patients should be monitored regularly for these potential complications.

Iganef-9 Tab is contraindicated in individuals with known hypersensitivity to budesonide or any excipients, and in patients with systemic fungal infections. Caution is also advised for those with uncontrolled infections, severe liver disease, or conditions that may be exacerbated by glucocorticoids.